• PNS203 USE OF DISCRETE CHOICE EXPERIMENTS TO INFORM HTA DECISION MAKING.

    Nov 1, 2019, 00:00

  • PDB122 REAL-WORLD INSULIN THERAPY IN GERMAN TYPE 2 DIABETES MELLITUS PATIENTS: PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND INSULIN DOSAGE

    Nov 1, 2019, 00:00

  • PMS31 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDG108 CLINICAL OUTCOMES ON SWITCHING BETWEEN NEWER P2Y12 RECEPTOR INHIBITORS AND CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PIH60 PEDIATRIC PATIENT ENGAGEMENT: USING PATIENT INSIGHTS TO IMPROVE STUDY DESIGN

    Nov 1, 2019, 00:00

  • PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PNS55 THE COST OF MEDICATION ERRORS IN PUBLIC HEALTH FACILITIES OF EASTERN REGION, GHANA.

    Nov 1, 2019, 00:00

  • PCN435 IMPROVED ESTIMATES OF EXTRAPOLATED MEAN SURVIVAL TIMES USING FINITE MIXTURE MODELS: REDUCING UNCERTAINTY IN COST EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PMU116 NICE MEDICAL TECHNOLOGIES GUIDANCE: IMPACT BEYOND THE UK

    Nov 1, 2019, 00:00

  • PNS307 THE COMBINED USE OF TREEAGE SOFTWARE TO ACCELERATE MARKOV MODEL CONSTRUCTION WITHIN AN EXCEL USER INTERFACE

    Nov 1, 2019, 00:00

  • PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?

    Nov 1, 2019, 00:00

  • PIH65 IMPACT ON CARERS OF PAEDIATRIC PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PMS4 EFFICACY OF RENAL FUNCTION IN PATIENTS WITH EARLY DIABETIC NEPHROPATHY COMPLICATED WITH HYPERURICEMIA.

    Nov 1, 2019, 00:00

  • PRO148 PSYCHOMETRIC EVALUATION OF A MODIFIED VISUAL FUNCTION QUESTIONNAIRE (MVFQ-25) USING DATA FROM A PHASE III OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH INHERITED RETINAL DYSTROPHY CAUSED BY BIALLELIC RPE65 MUTATIONS

    Nov 1, 2019, 00:00

  • PMD9 INTRODUCING BUDGET IMPACT ANALYSIS COMPARING REUSABLE TO SINGLE-USE BRONCHOSCOPES WITHIN A LARGE UK UNIVERSITY HOSPITAL

    Nov 1, 2019, 00:00

  • PIH67 THE CHANGES OF COST FOR PREECLAMPSIA PREGNANCY AFTER THE ANGIOGENIC FACTORS (SFLT-1 AND PLGF) TESTS. PRELIMINARY DATA OF AN ECONOMIC MODEL BASED ON LOCAL RWD.

    Nov 1, 2019, 00:00

  • Multiple Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN38 IMPACT OF CERVICAL CANCER SCREENING TIME ON SURGICAL OUTCOMES

    Nov 1, 2019, 00:00

  • PNS157 WHY EMERGENCY ACCESS TO DRUG TECHNOLOGES IN POLAND DOES NOT WORK?

    Nov 1, 2019, 00:00

  • PIH24 COST-UTILITY ANALYSIS OF NEWBORN SCREENING PROGRAM BY TANDEM MASS SPECTROMETRY IN JAPAN

    Nov 1, 2019, 00:00

  • PDB71 ASSOCIATION OF SEVERE HYPOGLYCEMIA WITH ALL-CAUSE MORTALITY AND COMPLICATIONS AMONG PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

    Nov 1, 2019, 00:00

  • PCN12 USING CLINICAL DATA STANDARDS TO FACILITATE COMPARISONS OF ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES IN REAL WORLD CLINICAL CARE AND POOLED CLINICAL TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PMH54 IS THE OXCAP-MH CAPABILITY MEASURE A FEASIBLE AND PSYCHOMETRICALLY VALID TOOL FOR THE ROUTINE EVALUATION OF MENTAL HEALTH SERVICES?

    Nov 1, 2019, 00:00

  • PCV114 FEASIBILITY OF USING REAL WORLD EVIDENCE TO INFORM DECISIONS ON CONDUCTING A COST EFFECTIVENESS ANALYSIS: AN EXAMPLE OF STROKE RISK REDUCTION THERAPIES IN ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS)

    Nov 1, 2019, 00:00

  • PBI41 CHALLENGES AND OPPORTUNITIES FOR THE REIMBURSEMENT OF GENE THERAPIES - STAKEHOLDER INSIGHTS FROM GERMANY, SWEDEN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN466 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CLINICAL PRACTICE FOR IMMUNE-CHECKPOINT INHIBITORS (ICI)-TREATED PATIENTS: WHAT ARE PATIENTS' EXPERIENCES AND EXPECTATIONS? RESULTS FROM AN ONLINE PATIENT COMMUNITY RESEARCH

    Nov 1, 2019, 00:00

  • PRO150 A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUATIONS IN HAEMOPHILIA

    Nov 1, 2019, 00:00

  • PNS74 COST-EFFECTIVENESS AND RETURN-ON-INVESTMENT OF THE DYNAMIC WORK INTERVENTION

    Nov 1, 2019, 00:00

  • PND122 HEALTHCARE RESOURCE UTILIZATIONS AND COSTS AMONG PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - A COMPARISON OF PATIENTS WITH AND WITHOUT UPPER LIMB FUNCTION IMPAIRMENT

    Nov 1, 2019, 00:00

  • PCV72 CLINICAL AND ECONOMIC IMPLICATIONS OF USING NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION USING AVAILABLE EVIDENCE FROM REAL-WORLD EXPERIENCE

    Nov 1, 2019, 00:00

  • PMH36 ST. JOHN'S WORT THERAPY IS ASSOCIATED WITH A REDUCED INCIDENCE OF DEMENTIA IN PATIENTS TREATED IN GENERAL PRACTICES

    Nov 1, 2019, 00:00

  • PND48 BURDEN OF MULTIPLE SCLEROSIS IN GERMANY — A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PGI38 ASSESSMENT OF PROPULSIVES CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Nov 1, 2019, 00:00

  • NO Specific Disease - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION

    Nov 1, 2019, 00:00

  • PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

    Nov 1, 2019, 00:00

  • PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREA ...

    Nov 1, 2019, 00:00

  • PRO122 ECONOMIC EVALUATION OF NUSINERSEN IN SPINAL MUSCULAR ATROPHY: A COMPARISON OF NICE AND HAS OPINIONS

    Nov 1, 2019, 00:00

  • PNS337 IMPROVING ON CYCLE CORRECTIONS FOR TIME-HOMOGENEOUS MARKOV MODELS

    Nov 1, 2019, 00:00

  • Neurological Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PSU13 COST UTILITY ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY VERSUS OPEN RADICAL NEPHRECTOMY IN KOREAN PATIENTS WITH RENAL CANCER

    Nov 1, 2019, 00:00

  • PIN127 BIRTH COHORT SCREENING FOR HEPATITIS C: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS

    Nov 1, 2019, 00:00

  • CE3 COMPARATIVE EFFECTIVENESS AMONG SINGLE AGENT CHEMOTHERAPEUTICS IN THE TREATMENT OF TNBC USING TIME TO NEXT TREATMENT AS A SURROGATE FOR EFFICACY

    Nov 1, 2019, 00:00

  • PMU113 IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS?

    Nov 1, 2019, 00:00

  • PNS385 USING THE VARK MODEL TO AID QUALITATIVE DATA COLLECTION IN PEDIATRIC PATIENTS

    Nov 1, 2019, 00:00

  • PRO22 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ECONOMIC BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS136 MEDICAL DEVICES PRICE SETTING IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER

    Nov 1, 2019, 00:00

  • PNS106 FACTORS AFFECTING THE HEALTHCARE PROVIDERS KNOWLEDGE OF PROJECT MANAGEMENT

    Nov 1, 2019, 00:00

  • PNS382 ACCURACY OF PRO DATA SIGNIFICANTLY IMPROVES WITH SUBJECT TRAINING IN MIGRAINE CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING

    Nov 1, 2019, 00:00

  • PDB94 PREDICTIVE MODELS USING MACHINE LEARNING FOR MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG65 THE IMPACT OF OUT-OF-POCKET SPENDING ON THE PENETRATION OF GENERIC DRUGS AFTER THE EXPIRY OF THE MARKET EXCLUSIVITY

    Nov 1, 2019, 00:00

  • Multiple Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PIH35 RATES OF DELIVERY WITH COMPLICATING CONDITIONS AND POSTPARTUM COMPLICATION RATES FOLLOWING DELIVERY SURGE AMONG U.S. MOTHERS

    Nov 1, 2019, 00:00

  • PNS402 PERCEIVED BARRIERS TO ENSURING THE EFFECTIVE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS

    Nov 1, 2019, 00:00

  • PIN37 HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN CHILDREN IN THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS62 HEALTH ECONOMIC VALUE OF BLOOD IN GHANA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PNS225 CURRENT STATUS OF OUTCOMES-BASED AGREEMENTS IN SELECTED EUROPEAN COUNTRIES AND CANADA

    Nov 1, 2019, 00:00

  • PIH42 HEALTHCARE RESOURCE USE FOR THE MANAGEMENT OF POSTPARTUM HAEMORRHAGE IN FRANCE, ITALY, THE NETHERLANDS, AND THE UK

    Nov 1, 2019, 00:00

  • PND131 HOW WELL ARE MULTIPLE SCLEROSIS PATIENTS INFORMED ABOUT THEIR DISEASE AND THEIR TREATMENT: AN ANALYSIS OF DATA COLLECTED BY A NOVEL MOBILE APPLICATION (MS GEMEINSAM)

    Nov 1, 2019, 00:00

  • PMS29 HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN119 BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Nov 1, 2019, 00:00

  • PMD54 MEDICAL CAPITAL EQUIPMENT TENDER ANALYTICS: META ANALYSIS ON WIN/LOSS STUDIES

    Nov 1, 2019, 00:00

  • PNS155 ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES

    Nov 1, 2019, 00:00

  • PMU77 OPIOID USE PATTERNS AND HEALTHCARE USE AMONG INDIVIDUALS WITH COMORBID CHRONIC NON-CANCER PAIN AND OBSTRUCTIVE SLEEP APNEA

    Nov 1, 2019, 00:00

  • PNS156 CHANGES IN LEADING CAUSES OF DEATHS AND THE NUMBER OF HOSPITAL BEDS IN HUNGARY BETWEEN 2002 AND 2017

    Nov 1, 2019, 00:00

  • PMU110 OPTIMIZING EARLY ACCESS THROUGH ITALY'S PHARMACEUTICAL INNOVATION SYSTEM: KEY SUCCESS FACTORS FOR ATTAINING INNOVATIVE AND CONDITIONALLY INNOVATIVE STATUS

    Nov 1, 2019, 00:00

  • Cancer - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN515 A SURVEY OF CLINICAL PRACTICE FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PGI42 THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM?

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PND83 ACCESS TO INTRAVENOUS TISSUE-LIKE PLASMINOGEN ACTIVATOR (IV TPA) THERAPY AND MECHANICAL THROMBECTOMY (MT) FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN HUNGARY

    Nov 1, 2019, 00:00

  • PMD23 BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

    Nov 1, 2019, 00:00

  • PMU73 MONETIZATION OF ADDITIONAL BENEFIT OF ORPHAN DRUGS IN GERMAN ARBITRATION BOARD DECISIONS

    Nov 1, 2019, 00:00

  • PMS10 COMPARATIVE ANALYSIS OF HIP PROSTHESIS BY REVISION METHODS FOR LATERAL AND DIRECT ANTERIOR APPROACH

    Nov 1, 2019, 00:00

  • Surgery - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS37 SHOULD WE CONSTANTLY BE COUNTING WITH CONSTANT DISCOUNTING?

    Nov 1, 2019, 00:00

  • PDB36 EVALUATING THE IMPACT OF INSULIN PRICE FLUCTUATION IN THE USA ON THE HEALTHCARE EXPENDITURE IN T2DM

    Nov 1, 2019, 00:00

  • PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION

    Nov 1, 2019, 00:00

  • PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY

    Nov 1, 2019, 00:00

  • PCN19 RELATIONSHIP OF STATIN OR ANTI PLATELET AGENTS AND HEPATOCELLULAR CARCINOMA IN TREATMENT NAIVE PATIENTS WITH CHB

    Nov 1, 2019, 00:00

  • PNS212 AIFA'S NEW INNOVATIVENESS DESIGNATION: DRIVERS FOR AWARD AND COMPARISON TO FRENCH HTA ASSESSMENTS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS

    Nov 1, 2019, 00:00

  • PMU112 ADHERENCE: NUDGING INNOVATION OF OUTCOMES-BASED CONTRACTS TO REWARD BEHAVIOR

    Nov 1, 2019, 00:00

  • PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PGI47 PSYCHOMETRIC VALIDATION OF THE INTESTINAL GAS QUESTIONNAIRE (IGQ) FOR MEASURING GAS RELATED SYMPTOMS AND THEIR IMPACT ON DAILY LIFE

    Nov 1, 2019, 00:00

  • PMD16 HEALTH ECONOMIC VALUE OF BLOOD IN IVORY COAST: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PMH39 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED INSOMNIA BY INSOMNIA SYMPTOMS: 2018 NATIONAL SLEEP SURVEY

    Nov 1, 2019, 00:00

  • PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS

    Nov 1, 2019, 00:00

  • PIN93 REAL WORLD DATA EXAMINING THE EFFECT OF DIRECT ACTING ANTIVIRALS AMONG PATIENTS DEFINED BY FIBROSIS STAGE AND VIRAL LOAD

    Nov 1, 2019, 00:00

  • PMS2 EXAMINATION OF A SPORT-SPECIFIC DYNAMIC CORE STABILITY PROGRAMME AMONG FEMALE ACROBATIC ROCK AND ROLL DANCERS

    Nov 1, 2019, 00:00

  • PIH14 INCREMENTAL COSTS OF PREMATURITY AND LOW BIRTHWEIGHT

    Nov 1, 2019, 00:00

  • PIN75 WHAT WE KNOW NOW: REVISITING THE COST-EFFECTIVENESS OF CHICKENPOX VACCINATION USING AN AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS

    Nov 1, 2019, 00:00

  • PMH18 PREVENTING MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG ADULTS: A REVIEW OF THE COSTS OF COMPLEX INTERVENTIONS

    Nov 1, 2019, 00:00

  • PDG71 A STUDY OF PHARMACIST'S LEVEL OF AWARENESS ABOUT FIRST REIMBURSEMENT PROGRAM IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • CL2 SYSTEMATIC REVIEW AND METANALYSIS ON THE IMPACT OF MULTI-DRUG RESISTANT BACTERIA ON ECONOMIC AND CLINICAL OUTCOMES OF HEALTHCARE ACQUIRED INFECTIONS

    Nov 1, 2019, 00:00

  • Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

    Nov 1, 2019, 00:00

  • CV4 HOSPITALIZED WITH STROKE AT THE WEEKEND: ARE THERE HIGHER RISK OF EARLY DEATH AND HIGHER COSTS?

    Nov 1, 2019, 00:00

  • PIH34 THE ASSOCIATION BETWEEN ANTICHOLINERGIC MEDICINE AND COGNITION DECLINE IN OLDER ADULTS: A SYSTEMIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSY57 PATTERNS OF PHARMACOLOGICAL TREATMENT IN ADULT PATIENTS WITH ATOPIC DERMATITIS

    Nov 1, 2019, 00:00

  • PDG19 CHARACTERISTICS AND HEALTHCARE SERVICE USE OF PATIENTS WITH SCHIZOPHRENIA SWITCHING FROM ORAL TO LONG-ACTING INJECTABLE ANTIPSYCHOTICS

    Nov 1, 2019, 00:00

  • PNS75 PROPER INCORPORATION OF ADVERSE EVENTS FROM MEDICAL TREATMENTS (AEMT) IN HEALTH TECHOLOGY ASSESSMENTS (HTA)

    Nov 1, 2019, 00:00

  • PSY8 ECONOMIC EVALUATION OF GUSELKUMAB AND OTHER IL-INHIBITORS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY

    Nov 1, 2019, 00:00

  • PND69 COSTS OF MULTIPLE SCLEROSIS IN DENMARK: INFORMAL CAREGIVER'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN

    Nov 1, 2019, 00:00

  • PRO149 PATIENT ENGAGEMENT IN RESEARCH: THE EURORDIS PATIENT-LED COMMUNITY ADVISORY BOARDS (CABS)

    Nov 1, 2019, 00:00

  • PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PRO61 EPIDEMIOLOGY OF HEMOPHILIA IN GERMANY: RESULTS FROM A GERMAN STATUTORY HEALTH INSURANCE CLAIMS DATABASE-ANALYSIS

    Nov 1, 2019, 00:00

  • PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PDG10 IMPROVING THE BUSINESS MODEL OF VALUE ADDED MEDICINES: NEW VALUE ASSESSMENT FRAMEWORK IS NEEDED

    Nov 1, 2019, 00:00

  • PCN224 TREATMENT BENEFIT DISCONTINUATION: COMPARISON OF A PARTITIONED SURVIVAL ANALYSIS AND A SEMI-MARKOV MULTI-STATE MODEL APPROACH USING AN ONCOLOGY CASE STUDY

    Nov 1, 2019, 00:00

  • PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA

    Nov 1, 2019, 00:00

  • PCN471 ATTITUDE TOWARDS CERVICAL CANCER SCREENING ATTENDANCE AND NON-ATTENDANCE AMONG ROMANY AND NON-ROMANY WOMEN

    Nov 1, 2019, 00:00

  • PCN241 COSTS OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE TRANSCEND NHL 001 CLINICAL TRIAL: A MICRO-COSTING ST ...

    Nov 1, 2019, 00:00

  • PCV149 UNHEALTHY WEEKENDS OR MONDAY BLUES? INVESTIGATING THE WEEKLY PATTERN OF STROKES

    Nov 1, 2019, 00:00

  • Individual's Health - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN166 ECONOMIC EVALUATION OF ANTICANCER DRUGS: A SYSTEMATIC REVIEW ON COST-EFFECTIVENESS STUDIES BASED ON HEALTHCARE SYSTEM CLAIMS DATABASES

    Nov 1, 2019, 00:00

  • PCN322 TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY

    Nov 1, 2019, 00:00

  • PCV109 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS FOR THE MINIMALLY INVASIVE SUTURELESS AORTIC VALVE REPLACEMENT IN PATIENTS WITH AORTIC STENOSIS IN POLAND

    Nov 1, 2019, 00:00

  • PDG58 THE IMPACT OF ECONOMIC REGULATION ON EXPANSIVE DRUG LIST IN FRANCE BETWEEN 2008 AND 2018

    Nov 1, 2019, 00:00

  • PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE

    Nov 1, 2019, 00:00

  • PND103 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY?

    Nov 1, 2019, 00:00

  • PCN390 ANALYSIS OF INDIRECT TREATMENT COMPARISONS IN ONCOLOGY-RELATED HTA DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PRS54 THE SUITABILITY OF THE EQ-5D-5L IN ASTHMA PATIENTS

    Nov 1, 2019, 00:00

  • PDB68 ASSESSMENT OF RISK FOR DEVELOPMENT OF TYPE 2 DIABETES IN THE GREEK POPULATION

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCV153 HOW COSTLY IS POOR ADHERENCE TO PHARMACOLOGICAL TREATMENTS FOR CARDIOVASCULAR DISEASE? A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • NO Specific Disease - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG22 THE ECONOMIC IMPACT OF SERIOUS FLUOROQUINOLONE-RELATED ADVERSE EVENTS

    Nov 1, 2019, 00:00

  • PMS58 HEALTH TECHNOLOGY ASSESSMENT (HTA) OF EQUISTASI FOR THE TREATMENT OF PATIENTS WITH PARKINSONIAN POST-DYSKINESIA FALLS.

    Nov 1, 2019, 00:00

  • PCN311 OPTIMAL BREAST CANCER SCREENING POLICY STRATIFYING BY BREAST DENSITY

    Nov 1, 2019, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PRO19 THE ROLE PLAYED BY SOCIAL COSTS IN ECONOMIC EVALUATIONS OF RARE DISEASE INTERVENTIONS

    Nov 1, 2019, 00:00

  • PNS346 CAN META-ANALYSES HELP IN SYNTHESIZING DATA ACROSS HEALTH ECONOMIC STUDIES?

    Nov 1, 2019, 00:00

  • PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA)

    Nov 1, 2019, 00:00

  • PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS

    Nov 1, 2019, 00:00

  • PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB

    Nov 1, 2019, 00:00

  • PRS3 A SYSTEMATIC REVIEW OF SINGLE-INHALER TRIPLE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PCN154 INCORPORATING THE VALUE HEALTHY INDIVIDUALS PLACE ON GENEROUS INSURANCE COVERAGE OF SEVERE DISEASES: A STATED PREFERENCE SURVEY OF ADULT COHORTS WITH AND AT-RISK FOR LUNG CANCER

    Nov 1, 2019, 00:00

  • PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • Individual's Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PUK11 TOLVAPTAN REDUCES HEALTHCARE BURDEN IN PATIENTS WITH STAGE 1-3 ADPKD IN SPAIN

    Nov 1, 2019, 00:00

  • PDB53 BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS TYPE II IN RUSSIA

    Nov 1, 2019, 00:00

  • PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS)

    Nov 1, 2019, 00:00

  • Surgery - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Mental Health - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIH22 ESTIMATING THE PRODUCTIVITY BURDEN OF PEDIATRIC PNEUMOCOCCAL DISEASE IN THAILAND

    Nov 1, 2019, 00:00

  • PDG23 BUDGET IMPACT ANALYSIS OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF GEP-NET AND ACROMEGALY IN THE UK

    Nov 1, 2019, 00:00

  • PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PDG96 SURVEY ABOUT KNOWLEDGE OF NANOMEDICINES AMONG PHARMACISTS IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB128 A NATIONWIDE, OBSERVATIONAL STUDY ASSESSING ADHERENCE TO THE HELLENIC GUIDELINES FOR FOLLOW-UP, CLINICAL, AND LABORATORY EVALUATIONS, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE GLANCE™ STUDY

    Nov 1, 2019, 00:00

  • PBI54 BIOSIMILAR AND ORIGINATOR INFLIXIMAB AND ETANERCEPT: INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS IN THE UK

    Nov 1, 2019, 00:00

  • PCN416 NETWORK META-ANALYSIS FOR SURROGATE ENDPOINT EVALUATION IN ADVANCED COLORECTAL CANCER: A BAYESIAN APPROACH

    Nov 1, 2019, 00:00

  • PIH13 A COST-EFFECTIVENESS ANALYSIS OF ENTERAL LACTOFERRIN SUPPLEMENTATION FOR VERY PRETERM INFANTS: THE ELFIN TRIAL

    Nov 1, 2019, 00:00

  • PMH57 IMPACT ON QUALITY OF LIFE AND PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH DEPRESSION

    Nov 1, 2019, 00:00

  • PBI27 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • PNS101 ASSOCIATION BETWEEN RISK FACTORS AND SAFE DRUG DISPOSAL IN COMMUNITY: A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PDG4 TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON

    Nov 1, 2019, 00:00

  • PCN7 THE VALUE OF OBINUTUZUMAB FOR UNTREATED ADVANCED FOLLICULAR LYMPHOMA: AN ASSESSMENT BASED ON MULTICRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PNS247 THE IMPLICATIONS OF EUROPEAN JOINT CLINICAL ASSESSMENT FOR MEMBER STATE PRICING MARKET ACCESS

    Nov 1, 2019, 00:00

  • PCN14 MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDB70 CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY TREATED WITH BASAL INSULIN THERAPY: A POPULATION-BASED UK STUDY

    Nov 1, 2019, 00:00

  • PRO88 PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5

    Nov 1, 2019, 00:00

  • PNS152 WILLINGNESS TO PAY FOR SOCIAL HEALTH INSURANCE AND RELATED FACTORS AMONG POPULATION IN YOGYAKARTA PROVINCE, INDONESIA

    Nov 1, 2019, 00:00

  • PIN27 ECONOMIC AND QUALITY OF LIFE BURDEN OF PAEDIATRIC INFLUENZA IN AUSTRALIA

    Nov 1, 2019, 00:00

  • PCV132 APPLYING EUROQOL-5D IN MIDDLE EASTERN PATIENTS WITH CARDIOVASCULAR DISEASES (CVD); A SAUDI PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN514 REAL WORLD TREATMENT PATHWAYS OF DIFFUSE LARGE B-CELL LYMPHOMA IN GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN397 INCORPORATING RISK SCORES IN CRC SCREENING MODELS: A EXAMPLE FROM THE INCA-PHE CRC MODEL

    Nov 1, 2019, 00:00

  • PRO62 SYSTEMATIC LITERATURE REVIEW OF DISEASE BURDEN, COSTS AND MODELS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

    Nov 1, 2019, 00:00

  • PRO92 AN ANALYSIS OF ORPHAN MEDICINES EXPENDITURE IN IRAN, 2018

    Nov 1, 2019, 00:00

  • PSY51 PSYCHOMETRIC PERFORMANCE OF PLAQUE PSORIASIS PATIENT REPORTED OUTCOME NUMERIC RATING SCALES IN A PHASE 2B CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PCN275 THE GLOBAL EPIDEMIOLOGY OF PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB55 COST-EFFECTIVENESS ANALYSIS OF NONINVASIVE SCORES FOR THE SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG METABOLIC SYNDROME PATIENTS

    Nov 1, 2019, 00:00

  • PIH30 CHALLENGES FACED BY PEOPLE WITH PHYSICAL DISABILITIES IN ACCESSING SEXUAL AND REPRODUCTIVE HEALTH SERVICES IN EASTERN REGION OF NEPAL

    Nov 1, 2019, 00:00

  • PCV120 A STATISTICAL COMPARISON OF LOGISTIC REGRESSION VERSUS MACHINE LEARNING TREE-BASED CLASSIFICATION METHODS IN PREDICTING CORONARY HEART DISEASE USING REAL-WORLD PATIENT-LEVEL DATA

    Nov 1, 2019, 00:00

  • PMS5 THE EFFECT OF DANCE THERAPY ON DEVELOPMENT OF MOVEMENT IN CHILDREN WITH DOWN SYNDROME

    Nov 1, 2019, 00:00

  • PCV95 ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PMU41 THE ASSOCIATION BETWEEN MULTIMORBIDITY AND PERCEIVED WORKING CONDITIONS IN EUROPE

    Nov 1, 2019, 00:00

  • PNS5 RELATIVE EFFECT OF INTERVENTIONS IN ACTINIC KERATOSIS: FINDINGS FROM METHODOLOGICAL ASSESSMENT AND NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PCN323 CHANGE IN TREATMENT PARADIGM OF ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) IN THE ITALIAN REAL PRACTICE

    Nov 1, 2019, 00:00

  • PNS312 QUANTITATIVE AND QUALITATIVE ANALYSIS OF THE AMNOG ARBITRATION BOARD DECISION FACTORS FOR THE PRICING OF NEW ACTIVE SUBSTANCES IN GERMANY

    Nov 1, 2019, 00:00

  • PBI53 GENE THERAPY PREPAREDNESS IN EUROPE

    Nov 1, 2019, 00:00

  • PSS7 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN JAPAN

    Nov 1, 2019, 00:00

  • CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PBI44 REAL-WORLD EVIDENCE IN GENE THERAPIES: RECOMMENDATIONS VERSUS REALITY

    Nov 1, 2019, 00:00

  • PND3 IMPACT OF SOCIAL NETWORK INTERVENTIONS ON SCHIZOPHRENIA OUTCOMES

    Nov 1, 2019, 00:00

  • PUK32 PATIENT INSIGHTS FOR IMMUNOGLOBULIN A NEPHROPATHY (IGAN) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • PRS59 ADAPTION OF THE ADHERENCE BARRIERS QUESTIONNAIRE (ABQ) FOR USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PMD34 FRENCH COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEME FOR INNOVATIVE MEDICAL DEVICES: AN OVERVIEW SINCE ITS REDESIGN IN 2015

    Nov 1, 2019, 00:00

  • PDB80 DIABETIC MACULAR EDEMA IN EUROPE: THE IMPACT OF PAYER POLICY ON PRESCRIBING

    Nov 1, 2019, 00:00

  • PCN488 A SYSTEMATIC LITERATURE REVIEW OF STUDIES REPORTING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH METASTATIC PANCREATIC CANCER BEFORE OR AFTER TREATMENT

    Nov 1, 2019, 00:00

  • PMU38 COSTS-EFFECTIVITY, HEALTH ECONOMIC EVALUATION, SYSTEMATIC REVIEW AND METANALYSIS OF BARIATRIC SURGERY IN REDUCING OBESITY RELATED DISEASES, MORTALITY, DEPRESSION AND CANCER

    Nov 1, 2019, 00:00

  • PNS381 THE RISE OF THE SOCIAL MEDIA MACHINE: A REVIEW OF PATIENT-CENTERED RESEARCH UTILIZING SOCIAL MEDIA RESEARCH METHODS PRESENTED AT ISPOR (2010 -2018)

    Nov 1, 2019, 00:00

  • PMU119 WHAT ARE THE KEY CHALLENGES ENCOUNTERED IN THE DESIGN, CONDUCT AND ASSESSMENT OF PRAGMATIC TRIALS AND HOW ARE THEY ADDRESSED?

    Nov 1, 2019, 00:00

  • PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Nov 1, 2019, 00:00

  • Infectious Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • AD4 ESTIMATING THE RELIABILITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND IDENTIFYING THE REASONS FOR NON-ADHERENCE

    Nov 1, 2019, 00:00

  • PNS191 IMPLEMENTATION OF A NEW MODEL OF THE NURSING CARE MANAGEMENT IN THE REPUBLIC OF KAZAKHSTAN: POLICY BRIEF

    Nov 1, 2019, 00:00

  • PNS349 DEVELOPMENT OF PLAIN ENGLISH SUMMARIES OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REPORTS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IRELAND

    Nov 1, 2019, 00:00

  • PDB65 PRETRIAL MODELLING METHODS TO JUSTIFY AND INFORM THE DESIGN OF LARGE RCTS - EXPECTED VALUE OF SAMPLE INFORMATION FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT

    Nov 1, 2019, 00:00

  • PCN495 REAL WORLD STUDIES IN ONCO-HEMATOLOGY: WHICH PARAMETER SHOULD BE USED TO MEASURE THE EFFICACY OF TREATMENTS?

    Nov 1, 2019, 00:00

  • Stroke Warning Information and Faster Treatment (SWIFT): Cost-Effectiveness of a Stroke Preparedness Intervention

    Nov 1, 2019, 00:00

  • Cancer - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN24 TYROSINE KINASE INHIBITORS: REAL WORLD EVIDENCE ABOUT HEALTH OUTCOMES IN A MIDDLE INCOME COUNTRY

    Nov 1, 2019, 00:00

  • PNS172 TRENDS IN PRESCRIPTION MONITORING PROGRAM PATIENT QUERIES AND DELEGATE ACCESS

    Nov 1, 2019, 00:00

  • PNS292 BUDGET IMPACT OF SOFTWARE SUPPORTING SAFE, EFFECTIVE AND EFFICIENT WORKING OF NHS ACUTE CARE PROVIDERS: ACTUAL BUDGET IMPACT FOR IMPLEMENTATION SITE AND LOST OPPORTUNITY SAVING AND PROJECTED BUDGET IMPACT POTENTIAL FOR OTHER SITES

    Nov 1, 2019, 00:00

  • PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PMH42 TARGETED LITERATURE REVIEW (TLR) OF THE ECONOMIC BURDEN OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS)

    Nov 1, 2019, 00:00

  • PBI77 PAYING FOR CURES: AN ANALYSIS OF INNOVATIVE ACCESS AGREEMENTS FOR LICENSED GENE THERAPIES

    Nov 1, 2019, 00:00

  • PMH68 IMPLEMENTING AND INTERPRETING A PROPOSED NEW MEASURE FOR HEDIS® 2020: PHARMACOTHERAPY FOR OPIOID USE DISORDER (OUD)

    Nov 1, 2019, 00:00

  • PCN233 COST EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE VS BENDAMUSTINE ALONE FOR PATIENTS WHO DID NOT RESPOND OR PROGRESSED DURING OR AFTER RITUXIMAB OR A RITUXIMAB CONTAINING REGIMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PNS297 CLINICAL AND KEY OPINION LEADERS VALIDATION IN HEALTH ECONOMICS MODEL AND COMPARATIVE EFFECTIVENESS: A GUIDE FOR NON-EXPERT AUDIENCE

    Nov 1, 2019, 00:00

  • Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs [Editor's Choice]

    Nov 1, 2019, 00:00

  • Neurological Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PNS252 DO MARKET WITHDRAWALS IMPACT PATIENT ACCESS TO TREATMENT IN GERMANY?

    Nov 1, 2019, 00:00

  • PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY

    Nov 1, 2019, 00:00

  • PNS270 ASSESSING THE PUBLIC HEALTH BENEFIT OF A MEDICINE: AN ANALYSIS OF THE CRITERIA APPRAISED BY THE FRENCH HTA BODY SINCE THE PUBLICATION OF ITS UPDATED MISSION STATEMENT OF SEPTEMBER 2018

    Nov 1, 2019, 00:00

  • PMU90 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)

    Nov 1, 2019, 00:00

  • PMD12 UNDERSTANDING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN PUNE, INDIA

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCV18 THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMD21 ECONOMIC EVALUATION OF THE SFLT-1/PLGF RATIO TEST TO GUIDE THE MANAGEMENT OF CHINESE SUSPECTED PRE-ECLAMPSIA WOMEN

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV48 COST EFFECTIVENESS OF RIVAROXABAN IN CORONARY ARTERY DISEASE AND/OR PERIPHERAL ARTERY DISEASE FOR 5 DIFFEREN PATIENT SUB-GROUPS IN TURKEY

    Nov 1, 2019, 00:00

  • PNS125 SHOULD DRUG PRICES DIFFER BY INDICATION? RESULTS OF A CONSULTATION

    Nov 1, 2019, 00:00

  • PSY26 UNMET MEDICAL NEED OF PRURIGO NODULARIS

    Nov 1, 2019, 00:00

  • PNS76 A BAYESIAN PARAMETRIC APPROACH TO HANDLE MISSING LONGITUDINAL OUTCOME DATA IN TRIAL-BASED HEALTH ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PUK27 THE ECONOMIC IMPACT OF DIGITAL HEALTH INTERVENTIONS IN THE MANAGEMENT OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMU136 PSYCHOMETRIC PROPERTIES OF MALE SEXUAL HEALTH QUESTIONNAIRE (MSHQ), IN HIV AND HCV PATIENTS

    Nov 1, 2019, 00:00

  • PIH43 CAN USING POINT OF CARE BLOOD TESTS HELP INFORM DECISION MAKING FOR PATIENTS WITH ACUTE FRAILTY SYNDROME? A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PNS153 MOVING TOWARD UNIVERSAL HEALTH COVERAGE IN JORDAN

    Nov 1, 2019, 00:00

  • PSY50 PATIENT PREFERENCES FOR PATIENT-CENTERED HEALTHCARE IN THE TREATMENT OF HEMOPHILIA: A BEST-WORST SCALING CASE 3

    Nov 1, 2019, 00:00

  • PIN150 ANALYSIS OF TREATMENT SEQUENCES FROM THE FRENCH NATIONAL SNIIRAM DATABASE: CASE STUDY OF INCIDENT PEOPLE LIVING WITH HIV IN 2013

    Nov 1, 2019, 00:00

  • PRO94 EXPLORING POTENTIAL CLINICAL BENEFITS AND COST SAVINGS FROM IMPLEMENTING A STANDARDIZED DIGITAL REFERRAL PROCESS FOR DIAGNOSIS AND MANAGEMENT OF RARE DISEASES IN SPAIN: A CASE EXAMPLE FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

    Nov 1, 2019, 00:00

  • PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)

    Nov 1, 2019, 00:00

  • PCN94 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT DRUGS FOR FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • Individual's Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PIH23 ECONOMIC BURDEN OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT) PATIENT IN MALAYSIA: A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU28 CAVEATS IN COST-EFFECTIVENESS ANALYSIS OF REMOTE PATIENT MONITORING: IMPACT OF END-OF-LIFE ADJUSTMENT OF QALYS ON DECISION MAKING METRICS

    Nov 1, 2019, 00:00

  • PBI83 GOLIMUMAB IMPROVES QUALITY OF LIFE AND OTHER PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN REAL-WORLD CONDITIONS

    Nov 1, 2019, 00:00

  • PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS

    Nov 1, 2019, 00:00

  • PCN242 REDEFINING VALUE IN ONCOLOGY: APPLICATION OF MIXTURE CURE MODELS FOR ECONOMIC ANALYSES OF NOVEL THERAPIES FOR SMALL CELL LUNG CANCER (SCLC)

    Nov 1, 2019, 00:00

  • PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PCN459 DEVELOPMENT OF A PATIENT-CENTERED CONCEPTUAL MODEL DESCRIBING THE IMPACT OF LIVING WITH HEPATOCELLULAR CARCINOMA

    Nov 1, 2019, 00:00

  • PSU6 ECONOMIC IMPACT OF A VALIDATED INTRAOPERATIVE BLEEDING SCALE: A RETROSPECTIVE MULTICENTER REVIEW FROM THE US PROSCPECTIVE

    Nov 1, 2019, 00:00

  • PIN38 THE COST OF STIGMA ASSOCIATED WITH HIV: A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA

    Nov 1, 2019, 00:00

  • PDB31 TRENDS IN THE USES OF ANTI-OSTEOPOROTIC DRUGS IN TAIWAN FROM 2012 TO 2018

    Nov 1, 2019, 00:00

  • PDB17 HEALTH ECONOMIC EFFECTS OF THE UPDATED FOOT ULCER SUBMODEL IN THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK

    Nov 1, 2019, 00:00

  • PNS386 PATIENT PREFERENCES IN THE MEDICAL PRODUCT LIFECYCLE: INITIAL RESULTS FROM THE IMI PREFER PUBLIC-PRIVATE PROJECT

    Nov 1, 2019, 00:00

  • Injury Trauma - Medical Technologies

    Nov 1, 2019, 00:00

  • PNS28 ADVANCING VALUE ASSESSMENTS: HOW CAN A PARADIGM OF VALUE MEASUREMENT BEYOND QALY BE ENHANCED TO HOLISTICALLY CAPTURE WHAT TRULY MATTERS TO PATIENTS AND PAYERS?

    Nov 1, 2019, 00:00

  • PRO84 REGULATORY AND MARKET ACCESS LANDSCAPE FOR CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • IN2 IMPACT OF TESTING RAPID INITIATION ON HIV INCIDENCE IN FRANCE: RESULTS OF A TRANSMISSION MODEL

    Nov 1, 2019, 00:00

  • PCN298 IMPROVED DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • PNS242 BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA

    Nov 1, 2019, 00:00

  • PRO157 PREDICTING HEALTH UTILITIES FROM PATIENT-REPORTED OUTCOME MEASURES (PROMS) IN RARE DISEASES: A SYSTEMATIC REVIEW OF MAPPING STUDIES

    Nov 1, 2019, 00:00

  • PCN290 IMPLEMENTATION OF COMBINATION THERAPY PRICING RULES IN ONCOLOGY: LESSONS FROM MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PRS11 EVIDENCE SYNTHESIS IN PULMONARY ARTERIAL HYPERTENSION: A CRITICAL APPRAISAL

    Nov 1, 2019, 00:00

  • PNS317 FAILURE OR EFFECT: ATTRIBUTE FRAMING IN A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PIN128 BUDGET IMPACT ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PCN446 A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

    Nov 1, 2019, 00:00

  • PCN507 CAN TRANSFERABILITY OF CLINICAL TRIALS POPULATION TO REAL WORLD SETTING BE ASSESSED USING FRENCH NATIONAL HEALTHCARE DATABASE? A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCV59 HOSPITAL LENGTH OF STAY AMONG VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH APIXABAN AND WARFARIN IN ENGLAND

    Nov 1, 2019, 00:00

  • PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING

    Nov 1, 2019, 00:00

  • PBI17 BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILAR RITUXIMAB AND TRASTUZUMAB COMPARED TO INTRAVENOUS AND SUBCUTANEOUS ORIGINATORS IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UK

    Nov 1, 2019, 00:00

  • PAM5 A SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF INTERVENTIONS WITH A PERSONALIZED NUTRITION COMPONENT IN ADULTS

    Nov 1, 2019, 00:00

  • PCN360 SURROGATE ENDPOINT VALIDATION STUDIES SUBMITTED TO THE GERMAN HEALTH TECHNOLOGY ASSESSMENT AUTHORITY, THE FEDERAL JOINT COMMITTEE (G-BA). CASE STUDIES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PND121 ANTIPSYCHOTICS UTILIZATION AND DIRECT MEDICAL COSTS ASSOCIATED WITH SCHIZOPHRENIA IN CHINESE PATIENTS

    Nov 1, 2019, 00:00

  • PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS?

    Nov 1, 2019, 00:00

  • PSU3 ALTERATIONS IN PATIENT WEIGHT AND CLINICAL FACTORS FOLLOWING GASTRIC BYPASS SURGERY

    Nov 1, 2019, 00:00

  • Individual's Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN526 PHYSICIAN ACCEPTANCE OF REAL-WORLD EVIDENCE IN DRUG APPROVAL AND LABELING

    Nov 1, 2019, 00:00

  • PIH33 FREQUENCY AND NATURE OF INPATIENT TREATMENT OF MULTIPLE OSTEOCHONDROMA (MO) IN GERMANY FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • PND109 PATIENT PREFERENCE FOR DOSING REGIMEN AND PERCEPTION OF DOSING FLEXIBILITY WITH FREMANEZUMAB FOR CHRONIC OR EPISODIC MIGRAINE: RESULTS FROM A WEB-BASED, PATIENT SURVEY FOLLOWING COMPLETION OF A 1-YEAR EXTENSION STUDY

    Nov 1, 2019, 00:00

  • PCN251 THE INCIDENCE OF SOFT TISSUE SARCOMA OVER THE NEXT TWO DECADES (2018-2040)

    Nov 1, 2019, 00:00

  • PCN197 BUDGET IMPACT OF LUNG CANCER SCREENING WITH LOW-DOSE COMPUTERIZED TOMOGRAPHY FOR SMOKING GROUPS

    Nov 1, 2019, 00:00

  • PIH3 VARIATIONS IN DURATION OF MECHANICAL VENTILATION IN VERY LOW BIRTH WEIGHT INFANTS IN JAPAN

    Nov 1, 2019, 00:00

  • PBI58 RESISTANCE TO OR SUPPORT OF BIOSIMILARS' MARKET PENETRATION? A SYSTEMATIC REVIEW OF EUROPEAN STAKEHOLDERS' BEHAVIOURS

    Nov 1, 2019, 00:00

  • PNS79 DETERMINING THE BASELINE STRATEGY IN A COST-EFFECTIVENESS ANALYSIS WITH TREATMENT SEQUENCES

    Nov 1, 2019, 00:00

  • PRO91 UTILITY OF REAL WORLD EVIDENCE DATA TO SUPPORT MARKET ACCESS OF RARE ONCOLOGY INDICATIONS IN EU5

    Nov 1, 2019, 00:00

  • Multiple Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand

    Oct 1, 2019, 00:00

  • Risk of Dependency: A Challenge for Health and Social Care Planning--Observational Stroke Cohort

    Oct 1, 2019, 00:00

  • A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

    Oct 1, 2019, 00:00

  • A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist–Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)

    Oct 1, 2019, 00:00

  • Estimators Used in Multisite Healthcare Costing Studies in Low- and Middle-Income Countries: A Systematic Review and Simulation Study

    Oct 1, 2019, 00:00

  • Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma

    Oct 1, 2019, 00:00

  • Table of Contents

    Oct 1, 2019, 00:00

  • A Comparison of National Guidelines for Network Meta-Analysis

    Oct 1, 2019, 00:00

  • Choosing Video Instead of In-Clinic Consultations in Primary Care in Israel: Discrete Choice Experiment Among Key Stakeholders—Patients, Primary Care Physicians, and Policy Makers

    Oct 1, 2019, 00:00

  • On the Optimization of Bayesian D-Efficient Discrete Choice Experiment Designs for the Estimation of QALY Tariffs That Are Corrected for Nonlinear Time Preferences [Editor's Choice]

    Oct 1, 2019, 00:00

  • Copyright/Subscription

    Oct 1, 2019, 00:00

  • External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data

    Oct 1, 2019, 00:00

  • Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice

    Oct 1, 2019, 00:00

  • Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Review [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities

    Oct 1, 2019, 00:00

  • Editorial Board

    Sep 26, 2019, 08:53

  • Copyright/Subscription

    Sep 9, 2019, 08:11

  • Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time

    Sep 1, 2019, 00:00

  • A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions

    Sep 1, 2019, 00:00

  • Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012

    Sep 1, 2019, 00:00

  • Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms

    Sep 1, 2019, 00:00

  • Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models [Editor's Choice]

    Sep 1, 2019, 00:00

  • Evaluation of the Association Between Health State Utilities and Obesity in Sub-Saharan Africa: Evidence From World Health Organization Study on Global AGEing and Adult Health Wave 2

    Sep 1, 2019, 00:00

  • Barriers and Facilitators to Model Replication Within Health Economics [Editor's Choice]

    Sep 1, 2019, 00:00

  • Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer

    Sep 1, 2019, 00:00

  • Adjusting for Inflation and Currency Changes Within Health Economic Studies

    Sep 1, 2019, 00:00

  • Editorial Board

    Sep 1, 2019, 00:00

  • Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia

    Sep 1, 2019, 00:00

  • As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time? [Editor's Choice]

    Sep 1, 2019, 00:00

  • Development and Psychometric Validation of an Instrument to Identify Barriers to Self-Care Among Spanish Patients With Type 2 Diabetes on the Basis of Theory of Planned Behavior

    Sep 1, 2019, 00:00

  • Table of Contents

    Sep 1, 2019, 00:00

  • Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy

    Sep 1, 2019, 00:00

  • Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions

    Sep 1, 2019, 00:00

  • Editorial Board

    Aug 16, 2019, 09:04

  • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre

    Aug 1, 2019, 00:00

  • Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure

    Aug 1, 2019, 00:00

  • Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data

    Aug 1, 2019, 00:00

  • United States Valuation of EQ-5D-5L Health States Using an International Protocol

    Aug 1, 2019, 00:00

  • Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis

    Aug 1, 2019, 00:00

  • PROM Validation Using Paper-Based or Online Surveys: Data Collection Methods Affect the Sociodemographic and Health Profile of the Sample

    Aug 1, 2019, 00:00

  • When Opportunity Knocks, What Does It Say?

    Aug 1, 2019, 00:00

  • Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications

    Aug 1, 2019, 00:00

  • A Scoping Review of Investment Cases for Vaccines and Immunization Programs

    Aug 1, 2019, 00:00

  • Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment [Editor's Choice]

    Aug 1, 2019, 00:00

  • Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration [Editor's Choice]

    Aug 1, 2019, 00:00

  • An Ethical Analysis of Coverage With Evidence Development [Editor's Choice]

    Aug 1, 2019, 00:00

  • Table of Contents

    Aug 1, 2019, 00:00

  • Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model

    Aug 1, 2019, 00:00

  • Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration–Approved Gene Therapy and Implications for Future One-Time Therapies

    Aug 1, 2019, 00:00

  • Author Reply

    Aug 1, 2019, 00:00

  • Copyright/Subscription

    Aug 1, 2019, 00:00

  • Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015 [Editor's Choice]

    Aug 1, 2019, 00:00

  • Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L

    Aug 1, 2019, 00:00

  • Editorial Board

    Jul 2, 2019, 09:19

  • Time-Driven Activity-Based Costing in Urologic Surgery Cycles of Care

    Jul 1, 2019, 00:00

  • Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

    Jul 1, 2019, 00:00

  • Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2

    Jul 1, 2019, 00:00

  • How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence

    Jul 1, 2019, 00:00

  • Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory? [Editor's Choice]

    Jul 1, 2019, 00:00

  • How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma

    Jul 1, 2019, 00:00

  • Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study

    Jul 1, 2019, 00:00

  • Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy

    Jul 1, 2019, 00:00

  • Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States

    Jul 1, 2019, 00:00

  • The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory

    Jul 1, 2019, 00:00

  • Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers

    Jul 1, 2019, 00:00

  • Machine Learning for Health Services Researchers [Editor's Choice]

    Jul 1, 2019, 00:00

  • Table of Contents

    Jul 1, 2019, 00:00

  • Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?

    Jul 1, 2019, 00:00

  • A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis

    Jul 1, 2019, 00:00

  • ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

    Jul 1, 2019, 00:00

  • Copyright/Subscription

    Jul 1, 2019, 00:00

  • Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

    Jun 1, 2019, 00:00

  • A Beginner's Guide to Understanding Curative Therapies

    Jun 1, 2019, 00:00

  • New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare—An Introduction

    Jun 1, 2019, 00:00

  • Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy [Editor's Choice]

    Jun 1, 2019, 00:00

  • Patient Preferences for Endometriosis Pain Treatments in the United States

    Jun 1, 2019, 00:00

  • Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

    Jun 1, 2019, 00:00

  • Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice

    Jun 1, 2019, 00:00

  • Table of Contents

    Jun 1, 2019, 00:00

  • Meaningful and Measurable Health Domains in Huntington’s Disease: Large-Scale Validation of the Huntington’s Disease Health-Related Quality of Life Questionnaire Across Severity Stages

    Jun 1, 2019, 00:00

  • Development and Validation of the MiPrep Survey: An Instrument Assessing Patients' Perceived Preparation for Medical Interventions Including Medical Imaging, Radiotherapy, and Surgery

    Jun 1, 2019, 00:00

  • Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

    Jun 1, 2019, 00:00

  • Current Value Frameworks—What's New?

    Jun 1, 2019, 00:00

  • A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

    Jun 1, 2019, 00:00

  • Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument

    Jun 1, 2019, 00:00

  • Current Policy and Practice for Value-Based Pricing

    Jun 1, 2019, 00:00

  • Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

    Jun 1, 2019, 00:00

  • Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System [Editor's Choice]

    Jun 1, 2019, 00:00

  • Specific Value Assessment Considerations

    Jun 1, 2019, 00:00

  • Copyright/Subscription

    Jun 1, 2019, 00:00

  • Are Global Health Systems Ready for Transformative Therapies?

    Jun 1, 2019, 00:00

  • Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? [Editor's Choice]

    Jun 1, 2019, 00:00

  • Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

    Jun 1, 2019, 00:00

  • Guide for Authors

    Jun 1, 2019, 00:00

  • Editorial Board

    Jun 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57 (current)
  • 58
  • 59
  • 60
  • »